3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Colorectal Neoplasms
4
Rectal Neoplasms
3
Diarrhea
3
Carcinoid Tumor
3
Gastro-enteropancreatic neuroendocrine tumor
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Malignant Carcinoid Syndrome
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma
1
Breast Neoplasms
1
Anus Neoplasms
1
Adenoma, Islet Cell
1
Interventions
lanreotide
1
cabozantinib
1
X-Rays
1
Sunitinib
1
Specimen Handling
1
Phantoms, Imaging
1
Octreotide
1
Magnetic Resonance Spectroscopy
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Adenoma, Islet Cell
×
Octreotide
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled